Physician profile
Micah Thompson
NPI 1821108838
$2,660.27
in general payments reported to CMS, 2019-2025
32 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $201 · 2021: $440 · 2022: $194 · 2023: $409 · 2024: $610 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $362.51 | 2021-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $360.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $318.72 | 2019-2025 | Evenity, Prolia, Repatha |
| Novartis Pharmaceuticals Corporation | $258.20 | 2019-2024 | |
| Novo Nordisk INC | $212.03 | 2019-2024 | Wegovy |
| Pfizer INC. | $97.21 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $91.13 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $90.84 | 2024-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $88.96 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $57.80 | 2019-2024 | Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $48.27 | 2025 | |
| Phathom Pharmaceuticals, INC. | $45.11 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $44.34 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.09 | 2019-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $41.59 | 2023-2024 | Injectafer |
| Sanofi Pasteur INC. | $41.01 | 2023-2024 | |
| Astellas Pharma US INC | $40.74 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.67 | 2019-2021 | |
| Mylan Specialty L.P. | $34.01 | 2023 | Yupelri |
| Allergan, INC. | $29.14 | 2019 | |
| Amneal Pharmaceuticals LLC | $28.41 | 2021-2022 | |
| Amarin Pharma, INC. | $27.18 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $24.79 | 2021 | |
| Shield Therapeutics INC | $22.40 | 2022 | |
| Itamar Medical INC | $22.37 | 2024 | Watchpatone |
| Neos Therapeutics, LP | $18.91 | 2019 | |
| Idorsia Pharmaceuticals US INC | $17.70 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.35 | 2022 | |
| Merck Sharp & Dohme LLC | $17.10 | 2020 | |
| Radius Health, INC. | $14.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micah Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.